Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jesse Sussell ◽  
Gurleen Singh Jhuti ◽  
Vincent Antao ◽  
Oscar Herrera-Restrepo ◽  
Elizabeth Wehler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cost Effectiveness ◽  
Early Breast Cancer ◽  
Adjuvant Treatment ◽  
The United States ◽  
Cost Effectiveness Analysis ◽  
Trastuzumab Emtansine ◽  
Effectiveness Analysis

Therapie des Mammakarzinoms – Ist die zusätzliche Gabe von Pertuzumab kosteneffektiv?

2020 ◽  
Vol 25 (01) ◽  
pp. 6-6
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cost Effectiveness ◽  
Adjuvant Treatment ◽  
The United States ◽  
Cost Effectiveness Analysis ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Effectiveness Analysis ◽  
Positive Breast Cancer

Garrison L et al. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. Value Health 2019: 22(4): 408–415 Bis zu 20 % der Frauen, die von Brustkrebs betroffenen sind, zeigen eine erhöhte Konzentration des Humanen Epidermalen Wachstumsfaktor-Rezeptors 2 (HER2). HER2-positiver Brustkrebs führt im Verlauf häufig zu Rezidiven und bedarf einer zielgerichteten Therapie. Garrison et al. untersuchten in diesem Zusammenhang die Kosten-Effektivität einer zusätzlichen Gabe von Pertuzumab.

scholarly journals Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Treatment for Early Breast Cancer

2014 ◽  
Vol 7 (1) ◽  
Author(s):  
Ali Aboutorabi ◽  
Mohammad Hadian ◽  
Hossein Ghaderi ◽  
Masoud Salehi ◽  
Maryam Ghiasipour
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Early Breast Cancer ◽  
Adjuvant Treatment ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis
Sign in / Sign up

Export Citation Format

Share Document